Law enforcement and public health officials say a surge in counterfeit versions of drugs that help with weight loss like Semaglutide (Ozempic, Wegovy) may be the worst since counterfeit erectile dysfunction drugs. (Reuters)

And several people were hospitalized in Austria after using a reportedly counterfeit version of semaglutide. (Reuters)

Sitagliptin (Zituvio) was FDA approved for adults with type 2 diabetes in 25-mg, 50-mg, and 100-mg strengths, Zydus Lifesciences announced.

The FDA also expanded the indication for vosoritide (Voxzogo) for achondroplasia with open epiphyses to include children of all ages with open growth plates, BioMarin said.

The investigational oral drug encaleret restored blood calcium levels and normalized levels of parathyroid hormone in people with autosomal dominant hypocalcemia type 1 in a 13-patient trial. (New England Journal of Medicine)

Researchers are paying more attention to potential ties between long COVID and menopause. (STAT)

About 7% of kids diagnosed with prediabetes progressed to full-blown type 2 diabetes over a 7-year period. (Journal of the Endocrine Society)

Reuters reported that Eli Lilly used a Switzerland-based contract drugmaker to produce more tirzepatide (Mounjaro) in preparation for its possible FDA approval for weight management.

And Lilly reportedly is planning to test tirzepatide in kids as young as 6 with obesity in a clinical trial. (Bloomberg)

People who consumed more than one serving of red meat daily had a 50% higher risk of type 2 diabetes. (American Journal of Clinical Nutrition)

Every doubling of exposure to the endocrine-disrupting PFAS chemical perfluorooctanesulfonic acid (n-PFOS) was linked with a 56% increased risk of thyroid cancer. (eBioMedicine)

Novo Nordisk pulled the plug early on the once-weekly injectable semaglutide (Ozempic) kidney outcomes trial in people with type 2 diabetes and chronic kidney disease for efficacy.

But in response to the positive trial news of semaglutide (Ozempic) in kidney disease, dialysis firm DaVita suggested that the GLP-1 receptor agonist may only benefit some of these patients. (Reuters)